To avoid unnecessary and incorrect treatment, men with PC should receive a PSA test and Gleason score prior to initiating treatment. As more research is conducted, more information on the natural history of this disease can become available.
The causes of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) can be complex, and it is thought that the cancer arises from multistep processes involving cell growth and differentiation. Prostate cancer can also be caused by a number of environmental factors, including toxins and infections. However, further research is needed to understand how these causes of prostate cancer act.
There were around 2.6 million newly diagnosed cases of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) in 2013 (around 9% of those diagnosed with any type of cancer). This made up 21% of all men diagnosed with a cancer in 2013. And there are an estimated 18,800 deaths due to prostate cancer per year.\n\n- Cancer in the United States"
"Rhypsiada\n\nRhypsiada is a genus of moths of the family Crambidae described by Carl Friedrich Roewer in 1961.
The signs of prostate cancer are vague and often non-specific. They include general symptoms, such as increased urgency, reduced urination, nocturia and incontinence. These signs may have been caused by prostate cancer rather than benign prostatic abnormalities.
This survey confirms some of the conclusions in the literature that psychological therapy and the stress-reduction therapy of group and individual psychotherapy are useful in decreasing anxiety produced by the diagnosis of an occult malignancy, and that the use of medication for the treatment of the symptoms of distress is also important. For cancer patients specifically, the use of medical treatment should be individualized and discussed with the patient before the initiation of therapy.
The current study confirms both the safety and effectiveness of the three doso tions used, in terms of LDR and PSA response, irrespective of irradiation modality used.
In case of advanced bladder carcinoma in palliative setting, the new generation 3D-CRT has higher palliative and pain relief compared with previous 3D-CRT. In case of early bladder carcinoma, the 51.6Gy IMRT is more effective than the 36Gy CRT as well as the 9Gy CRT.
In recent years, new approaches have been made to treat and even prevent prostate cancer. The possibilities that exist now for using laser radiation for the treatment of prostate cancer and for creating immunosuppressive drugs that may lead to better patient survival is a most exciting hope to many physicians.
These data suggest a new and safer application of IMRT to the prostate and the pelvic lymph nodes, leading to a more homogeneous dose coverage with better plans. They also suggest that the therapeutic doses could be reduced by 15-25% without compromising the treatment efficacy in our patients.
The authors reviewed a diverse group of 486 patients treated by IMRT at St. Luke's Medical Center in New York over an 11-year period, and found no association, either positive or negative, between clinical factors and toxicity or dose to OARs in this cohort. As demonstrated by our data, the use of IMRT does not result in an increase in toxicity relative to conventional techniques of radiation therapy, and the dosages given at the 50% and 92% isodoses may exceed that prescribed by conventional techniques.
The common side effects of fractionating irradiation to the prostate are: irritation and mild pain at the treatment site, asymptomatic bleeding or rectal bleeding or rectal irritation. Symptoms of urethral toxicity included urgency and pain, and irritation and bleeding at the treatment site, and were usually more pronounced in the third, fourth, and fifth years after the treatment. The urethral toxicity induced by irradiation depends on the time after irradiation, dose delivered to the urethra, and treatment site of the radiation fields.